Clinical Trial Update: Safety and Efficacy Study of I-131 Tositumomab in Patients With Relapsed/Refractory Hodgkin's Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update on safety and efficacy of I-131 tositumomab in relapsed/refractory Hodgkin's lymphoma (Phase 1/Phase 2; completed).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma

Drugs mentioned

• I-131 tositumomab (tositumomab)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Hodgkin's Disease | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2018-08-01